Showing 2171-2180 of 5643 results for "".
- SpyGlass Pharma Unveils 1-Year Data of Its Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucomahttps://modernod.com/news/spyglass-pharma-unveils-1-year-data-of-its-drug-delivery-platform-implanted-during-routine-cataract-surgery-in-eyes-with-glaucoma/2482196/SpyGlass Pharma announced 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ IOL-based drug delivery platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation
- Registration Now Open for Neuro-Optometric Rehabilitation Association 2024 Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-association-2024-conference/2482187/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) 34th annual conference, September 19-22, at the Embassy Suites by Hilton Orlando, Lake Buena Vista South in Kissimmee, Florida. The NORA annual conference is a premier event for eye care a
- Cliara Awarded US Patent for Contact Lens Force Measurement Devicehttps://modernod.com/news/cliara-awarded-us-patent-for-contact-lens-force-measurement-device/2482179/Cliara has been granted a United States patent for a device designed to accurately measure the force required to remove gas-permeable contact lenses from the eye, according to a company news release. Cliara LLC is collaborating with BostonSight and LV Prasad Eye Institute
- Research: AI Has Perfect Detection Rate for Severe Cases of Retinopathy of Prematurity (ROP)https://modernod.com/news/research-ai-has-perfect-detection-rate-for-severe-cases-of-retinopathy-of-prematurity-rop/2482153/New research from Oregon Health & Science University (OHSU) and collaborators reveal that artificial intelligence technology can accurately and independently detect 100% of severe cases of retinopathy of prematurity (ROP). The research was
- Telios Pharma Announces Phase 2 Results for TL-925, a Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/telios-pharma-announces-successful-phase-2-results-for-tl-925-a-novel-treatment-for-dry-eye-disease/2482150/Telios Pharma announced topline results from its phase 2 study assessing TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor for individuals with moderate to severe dry eye disease (DED). This proof-of-concept, multicenter, randomized, double-masked study evaluated the
- Phase 1b/2a Trial of Exonate's Eye Drop Demonstrates Safety and Biological Activity in Treatment of DR and DMEhttps://modernod.com/news/phase-1b2a-trial-of-exonates-eye-drop-demonstrate-safety-and-biological-activity-in-treatment-of-dr-and-dme/2482148/UK-based Exonate announced data from a phase 1b/2a trial for lead candidate EXN407 demonstrating safety and tolerability of the drug candidate, as well as clear indications of biological activity, according to a company news release. The data position the company for further development
- Sandoz Closes Deal to Acquire Ranibizumab Biosimilar Cimerli from Coherushttps://modernod.com/news/sandoz-closes-deal-to-acquire-ranibizumab-biosimilar-cimerli-from-coherus/2482144/Sandoz has completed the acquisition of the US biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences. In January, in a move to pay down debt and focus on its oncology business, Coherus BioSciences entered into an agreement to divest its Cimerli (ranibiz
- Amring Pharmaceuticals Changes Name to Nordic Pharma Under New Ownerhttps://modernod.com/news/amring-pharmaceuticals-changes-name-to-nordic-pharma-under-new-owner/2482141/Amring Pharmaceuticals has changed its name to Nordic Pharma, effective today, following the change in ownership of the company from Sever Life Sciences to Nordic Group, a subsidiary of Sever Life Sciences, which occurred on June 1, 2023. The change in the corporate name
- Glaukos' iDose TR Now Commercially Availablehttps://modernod.com/news/glaukos-idose-tr-now-commercially-available/2482139/Glaukos' iDose TR (travoprost intracameral implant 75 mcg), which uses Celanese’s VitalDose EVA (Ethylene Vinyl Acetate) to provide sustained drug release for the treatment of glaucoma, is now commerically available, according to Celanese. The iDo
- Nicox Names New CEO; Restructures Debt to Focus on NCX 470 Pivotal Trialhttps://modernod.com/news/nicox-names-new-ceo-restructures-debt-to-focus-on-ncx-470-pivotal-trial/2482137/Nicox announced this week that its Board of Directors has promoted Gavin Spencer to Chief Executive Officer. He previously served as Executive Vice-President, Chief Business Officer & Head of Corporate Development. Mr. Gavin will be replacing Andreas Segerros, whose mandat